Julayi 2022: Ngokocwaningo lwakamuva olwenziwe yi-Emergen Research, imakethe yomhlaba wonke yokwelashwa kwamaseli e-CAR T ifinyelele kusayizi wama-USD 1.29 billion ngo-2021 futhi kulindeleke ukuthi ibhalise i-CAGR yemali engenayo yamaphesenti angama-24.9 phakathi nesikhathi sokubikezela. Izigameko ezikhulayo zomdlavuza emhlabeni wonke kanye nezinga elikhulayo lokufa okubangelwa umdlavuza kulindeleke ukuthi kube yizona ezihamba phambili zokukhula kwemali emakethe ye-CAR-T cell therapy emhlabeni jikelele phakathi nesikhathi sokubikezela. Ukunwetshwa kwemisebenzi yokuhlolwa komtholampilo ngokushesha okukhulu, ukwanda kokuhlangana nokutholwa, kanye nokukhanga kokunikelwayo kokuqala komphakathi konke kuyizici ezinomthelela ekukhuleni kwemali engenayo emakethe yomhlaba wonke ye-CAR T-cell therapy.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global I-CAR T-Cell Therapy market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the I-CAR T-Cell Therapy market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Okunye okutholakele okubalulekile okuvela embikweni kukhombisa lokho
In 2021, the segment of diffuse large B-cell i-lymphoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with i-chimeric antigen receptor T-cell therapy, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell i-non-Hodgkin lymphomas who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Izinkampani ezibalulekile ezisebenza emakethe njengamanje ziphenywa kabanzi kulo mbiko, njengamaphrofayili ezinkampani, iphothifoliyo yemikhiqizo, amasu okunweba, kanye nemifelandawonye yamasu. Ezinye izibonelo zalezi zinhlobo zemifelandawonye zifaka ukuhlanganiswa nokutholwa, ukusebenzisana, kanye nama-joint ventures. Ngaphezu kwalokhu, inikeza amaphuzu avelele mayelana nezimpumelelo zenkampani kanye nokuma kwezimali, kanye nemininingwane ngokufinyelela emakethe kanye nesimo senkampani emhlabeni jikelele.
Izinkampani ziphrofayili emakethe yomhlaba wonke ye-CAR T-Cell Therapy:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., kanye no-Eli Lilly and Company .
Funda kabanzi ngombiko wemakethe ye-CAR T-Cell Therapy yomhlaba wonke ku: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
